These days, research scientists, much like Rodney Dangerfield, can’t get any respect. The latest evidence of this arrived on Friday, when AstraZeneca (London) proposed to cut 3500 research and development (R&D) jobs by 2014. Read more »

Haiti is the only nation in the Latin American and Caribbean region still considered a least developed country (LDC) by the United Nations. After this month’s earthquake devastated the nation of 9.7 million, it has been heartwarming to see hundreds of disaster relief crews and humanitarian organizations respond to the crisis. Pharmaceutical companies have been part of the picture as well—delivering millions of dollars in funds and medicines, either directly to Haiti or through nonprofit organizations. GlaxoSmithKline (GSK) is among the many pharmaceutical manufacturers, including Pfizer, Abbott Laboratories, Amgen, Merck, Eli Lilly, contributing aid to Haiti. Read more »

Now that award season is here, it seems fitting that the pharma industry has announced the production of a new film. Wait, did I just write that? Yes, as did a slew of other surprised bloggers this week. Pharma is going Hollywood. Read more »

Vetter, a specialist in the aseptic filling of injection systems, opened a new 24,000-ft² facility in Chicago to manufacture preclinical, Phase I and Phase II clinical batches. The expansions, part of the new Vetter Develoment Services USA Inc., complement the company’s commercial-scale capabilities in Germany. PharmTech Europe Editor Fedra Pavlou, interviewed Peter Soelkner, managing director of Vetter Pharma International GmbH live from the AAPS 2009 show floor in Los Angeles last month. Listen to the podcast here.

See background article, “Vetter Expands Clinical- and Commercial-Scale Operations” by Patricia Van Arnum.

Complex Documents in the Pharmaceutical Industry Made Easy
Thursday, October 22, 2009 at 10:00 AM GMT (United Kingdom) Read more »